非脊柱骨转移立体定向放疗:指导治疗计划的国际实践模式调查
该研究邀请9位国际放射肿瘤专家对11例非脊柱骨转移(NSBM)病例进行SBRT治疗计划决策和剂量分割选择的调查。结果显示,全球在NSBM-SBRT技术和剂量分割上存在显著异质性,但专家们在选择生物等效剂量≤100 Gy10、剂量降级指征以及基于骨部位确定可接受剂量方案上达成一致。
要点
- 多数专家(56%)常规融合MRI与计划CT进行靶区勾画。
- 所有专家处方的生物等效剂量均≤100 Gy10,五分割方案(尤其35 Gy/5)最常见。
- 既往SBRT、既往常规放疗或承重骨伴中重度皮质侵蚀时推荐剂量降级。
核心结论
- 全球NSBM-SBRT在技术和剂量分割上存在显著异质性,支持制定共识指南的必要性。
- 专家一致认为应选择生物等效剂量≤100 Gy10的剂量方案,并明确了剂量降级的指征。
研究设计与样本
- 邀请9位在NSBM-SBRT方面有专长的国际放射肿瘤专家参与调查。
- 提供11例NSBM病例的肿瘤区勾画、计划CT和MRI图像,覆盖长骨、骨盆骨和胸廓骨。
- 调查专家治疗计划决策和剂量分割选择,并进行描述性分析。
主要发现
- 所有专家均完成调查,56%常规融合MRI与计划CT进行靶区勾画。
- 剂量分割方案包括单次18-24 Gy/1、2次24 Gy/2、3次28-30 Gy/3、5次30-50 Gy/5和10次42-50 Gy/10。
- 所有方案的生物等效剂量均≤100 Gy10。
- 五分割方案最常见,其中35 Gy/5被56%的专家在至少1例中选用;至少3位专家使用的其他方案有20 Gy/1、30 Gy/3和30 Gy/5。
- 3位专家使用同步整合 boost 处方两个剂量体积,分别针对GTV和CTV或CTV1和CTV2。
关键数值与推荐
- 所有专家处方的生物等效剂量均≤100 Gy10。
- 五分割方案35 Gy/5被56%的专家在至少1例中选用。
- 至少3位专家使用的其他剂量分割:20 Gy/1、30 Gy/3、30 Gy/5。
- 同步整合 boost 示例:30 Gy/3至GTV或CTV1,15-24 Gy/3至CTV或CTV2。
临床怎么用
- NSBM-SBRT计划时应常规融合MRI与计划CT以辅助靶区勾画。
- 选择剂量分割时确保生物等效剂量≤100 Gy10。
- 既往SBRT、既往常规放疗或承重骨伴中重度皮质侵蚀时考虑剂量降级。
- 根据骨转移部位选择可接受的剂量分割方案。
局限性
- 调查仅基于9位专家对11例病例的决策,样本量小。
- 结果反映专家实践模式而非临床结局。
- 未报告患者预后或毒性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic body radiation therapy (SBRT) is increasingly used for nonspine bone metastases (NSBM); however, there are limited data informing treatment planning. We surveyed international experts to better understand worldwide practice patterns in delivering NSBM-SBRT. METHODS AND MATERIALS: Nine international radiation oncologists were invited to participate based on demonstrated expertise with NSBM-SBRT. Experts were sent gross tumor volume contours and planning computed tomography and magnetic resonance images for 11 NSBM cases that covered a range of bony sites, including metastases to long bones (femur, humerus), pelvic bones (ilium, ischium, acetabulum, pubic symphysis), and thoracic bones (rib, sternum, scapula, clavicle). Experts were surveyed regarding treatment planning decisions and dose-fractionation selection. Descriptive analysis was conducted on the survey data. RESULTS: All experts participated and completed the survey. Most (56%) routinely fused magnetic resonance imaging with planning computed tomography imaging for target delineation. Dose fractionation schedules included single-fraction (18-24 Gy/1), 2 fractions (24 Gy/2), 3 fractions (28-30 Gy/3), 5 fractions (30-50 Gy/5), and 10 fractions (42-50 Gy/10). Although doses varied considerably, all had a biological equivalent dose of ≤100 Gy10. Five-fraction schedules were most common, specifically 35 Gy/5, with 56% opting for this dose-fractionation in at least 1 case. Other dose-fractionation schedules used by at least 3 experts were 20 Gy/1, 30 Gy/3, and 30 Gy/5. Three experts prescribed 2 dose volumes using a simultaneous integrated boost. The 2 dose volumes were either the gross tumor volume and clinical target volume (CTV) or a smaller CTV (CTV1) encompassed within a larger CTV (CTV2) (eg, 30 Gy/3 to gross tumor volume or CTV1 and 15-24 Gy/3 to CTV or CTV2). Dose de-escalation was recommended by all experts in the setting of previous SBRT and by most in the context of previous convevoltherapy or in weight-bearing bones, especially if moderate-to-severe cortical erosion was present. CONCLUSIONS: Significant heterogeneity exists worldwide in radiation technique and dose-fractionation for NSBM-SBRT, which supports the need for consensus guidelines to inform practice and trial design. Nonetheless, these data demonstrate expert agreement on selecting dose schedules with a biologically effective dose ≤100 Gy10, reasons for dose de-escalation, and in determining acceptable dose schedules based on bony site.
引用
- Nguyen TK, Sahgal A, Dagan R, et al. Stereotactic Body Radiation Therapy for Nonspine Bone Metastases: International Practice Patterns to Guide Treatment Planning. Pract Radiat Oncol. 2020. PMID: 32171852. doi:10.1016/j.prro.2020.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。